Misonix (NASDAQ:MSON) was upgraded by investment analysts at TheStreet from a “d+” rating to a “c” rating in a research note issued to investors on Tuesday, TheStreetRatingsTable reports.
NASDAQ MSON opened at $19.04 on Tuesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.13 and a quick ratio of 2.43. The stock has a market capitalization of $331.14 million, a PE ratio of -13.04 and a beta of 1.48. Misonix has a 1 year low of $9.06 and a 1 year high of $20.71. The business’s 50-day moving average is $18.80 and its 200 day moving average is $14.57.
Misonix (NASDAQ:MSON) last posted its earnings results on Thursday, February 4th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.22. The company had revenue of $18.26 million for the quarter. Misonix had a negative return on equity of 16.94% and a negative net margin of 35.03%.
Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets minimally invasive surgical ultrasonic medical devices in the United States and internationally. The company's products include BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting and sculpting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.
Recommended Story: Dividend Kings
Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.